الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Renal transplantation is the preferred treatment for end-stage renal disease. However, there is a hazard of acquiring numerous blood diseases after a kidney transplant . Blood disorders occurring after renal transplantation can be divided into two main groups: (1) Common disorders which are: Post-Transplant Anemia (PTA), Post-Transplant Lymphoproliferative Disorder (PTLPD), Post-Transplant Erythrocytosis (PTE), and Post-Transplant Cytopenia like (PTC, leukopenia/neutropenia, thrombocytopenia, and pancytopenia); and (2)Uncommon but serious disorders which are: Hemophagocytic Syndrome (HPS), Thrombotic Microangiopathy (TMA), Therapy-related Myelodysplasia (t-MDS), and Therapy-related Acute Myeloid Leukemia (t-AML) . PTLPD is a complex illness with a wide range of histopathological manifestations, ranging from non-malignant (mononucleosis-like) lymphoproliferations to malignant lymphoproliferations. The various structural abnormalities are assumed to represent several - and sometimes sequential - stages of disease. EBV establishes one of three latency patterns depending on the viral gene expression pattern; the latency proteins play a significant role in altering important signaling pathways that promote lymphomagenesis. Also (EBV+) & (DLBCL) belong to both latency type II and III patterns. Many studies show the role of the human leucocyte antigen (HLA) system in tumor antigen presentation could be involved in susceptibility and disease control, Hodgkin lymphoma (HL) was the first disease to be a combine with HLA alleles. Aim of the work: Predicative study of latent membrane protein 1 & human leucocyte antigen in recipient post renal transplant lymphoproliferative disorders. Subjects & methods: This study included all first-time kidney transplanted recipients (130 patients) at a single center between 2010 and 2022. All patients were included for whom recipient and donor HLA typing data were available. In keeping with the standard HLA typing for solid-organ transplants, antigen-level typing was recorded for donors and recipients. For HLA class I, HLA-A and -B were analysed and, HLA class II, HLA-DRB1 also analysed. Results: We report several predictive-modifying HLA alleles and LMP1 in prediction of nondestructive form PTLPD, which can be clinically suitable in modified monitoring schemes after transplantation.Our study provided evidence that LMP1, HLA A30, HLA B18 & HLA DRB1 04 alleles are good predictors of development of early non distractive form of PTLPD after kidney transplant.